Technical Analysis for BIIB - Biogen Idec Inc.
|Grade||Last Price||% Change||Price Change|
BIIB closed down 2.51 percent on Friday, February 16, 2018, on 2.05 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical BIIB trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 16||180 Bearish Setup||Bearish Swing Setup||0.00%|
|Feb 16||Boomer Sell Setup||Bearish Swing Setup||0.00%|
|Feb 16||Inside Day||Range Contraction||0.00%|
|Feb 16||Wide Bands||Range Expansion||0.00%|
|Feb 16||Oversold Stochastic||Weakness||0.00%|
|Feb 15||Jack-in-the-Box Bearish||Bearish Swing Setup||-2.51%|
|Feb 15||Calm After Storm||Range Contraction||-2.51%|
|Feb 15||Lower Bollinger Band Walk||Weakness||-2.51%|
|Feb 15||Multiple of Ten Bearish||Other||-2.51%|
|Feb 15||Inside Day||Range Contraction||-2.51%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BIIB news...
|52 Week High||370.57|
|52 Week Low||244.28|
|200-Day Moving Average||302.8442|
|50-Day Moving Average||331.0568|
|20-Day Moving Average||332.4415|
|10-Day Moving Average||313.758|
|Average True Range||11.3889|
|Chandelier Exit (Long, 3 ATRs )||336.4033|
|Chandelier Exit (Short, 3 ATRs )||322.1667|
|Upper Bollinger Band||375.4498|
|Lower Bollinger Band||289.4332|
|Percent B (%b)||0.03|
|MACD Signal Line||-4.421|
|Market Cap||61.71 Billion|
|Num Shares||211 Million|
|Price-to-Earnings (P/E) Ratio||19.15|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||303.30|
|Resistance 3 (R3)||304.24||301.37||301.40|
|Resistance 2 (R2)||301.37||298.46||300.90||300.76|
|Resistance 1 (R1)||296.62||296.66||295.19||295.68||300.12|
|Support 1 (S1)||289.00||290.84||287.57||288.06||283.62|
|Support 2 (S2)||286.13||289.04||285.66||282.98|
|Support 3 (S3)||281.38||286.13||282.35|
|Support 4 (S4)||280.44|